CERO (CERo Therapeutics Holdings) Net Income From Continuing Operations : $-11.78 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CERo Therapeutics Holdings's net income from continuing operations for the three months ended in Mar. 2025 was $-5.11 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.78 Mil.

CERo Therapeutics Holdings Net Income From Continuing Operations Historical Data

The historical data trend for CERo Therapeutics Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Net Income From Continuing Operations Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

-10.63

-11.83

-7.29

CERo Therapeutics Holdings Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial							-	-2.45	-4.23	-	-5.11

CERo Therapeutics Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.78 Mil.

CERo Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.